Sildenafil citrate ODF is under clinical development by Avenir Wellness Solutions and currently in Phase I for Erectile Dysfunction. According to GlobalData, Phase I drugs for Erectile Dysfunction have an 88% phase transition success rate (PTSR) indication benchmark for progressing into Phase II. GlobalData’s report assesses how Sildenafil citrate ODF’s drug-specific PTSR and Likelihood of Approval (LoA) scores compare to the indication benchmarks. Buy the report here.
GlobalData tracks drug-specific phase transition and likelihood of approval scores, in addition to indication benchmarks based off 18 years of historical drug development data. Attributes of the drug, company and its clinical trials play a fundamental role in drug-specific PTSR and likelihood of approval.
Sildenafil citrate ODF overview
Sildenafil(Cureform) is a benzenesulfonamide derivative acts as vasoactive agent. It is formulated as for oral dissolving film. Sildenafil is indicated for the treatment of erectile dysfunction.
Sildenafil is under development for the treatment of erectile dysfunction. The drug candidate is formulated as thin oral dissolving film. It acts by targeting phosphodiesterase type 5. It is developed based on CUREfilm ODF technology platform.
Avenir Wellness Solutions overview
Avenir Wellness Solutions (Avenir Wellness) is a pharmaceutical cannabis company that provides innovative drug delivery. Its technology enables drugs to bypass the gastrointestinal tract, avoiding gastrointestinal side effects and inactivation in the gut and liver. The company is headquartered in Sherman Oaks, California, the US.
For a complete picture of Sildenafil citrate ODF’s drug-specific PTSR and LoA scores, buy the report here.
Data Insights
From
The gold standard of business intelligence.
Blending expert knowledge with cutting-edge technology, GlobalData’s unrivalled proprietary data will enable you to decode what’s happening in your market. You can make better informed decisions and gain a future-proof advantage over your competitors.
GlobalData, the leading provider of industry intelligence, provided the underlying data, research, and analysis used to produce this article.
GlobalData’s Likelihood of Approval analytics tool dynamically assesses and predicts how likely a drug will move to the next stage in clinical development (PTSR), as well as how likely the drug will be approved (LoA). This is based on a combination of machine learning and a proprietary algorithm to process data points from various databases found on GlobalData’s Pharmaceutical Intelligence Center.
